menu
    • menu
    [{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Starbloom Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Neutrophil based Leukocyte Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LIfT Biosciences \/ Starbloom Capital","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Starbloom Capital"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Minaris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Neutrophil Progenitor-based Leukocyte Infusion Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LIfT Biosciences \/ Minaris","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Minaris"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Immunomodulatory Alpha Neutrophil","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Alpha Neutrophil-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Innovate UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neutrophil-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Innovate UK"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Sijbrandij Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"Immunomodulatory Alpha Neutrophils","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Sijbrandij Foundation","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Sijbrandij Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by LIfT Biosciences

    Menu

    LIfT Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immunomodulatory Alpha Neutrophils

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Sijbrandij Foundation

                            Deal Size : $13.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LIfT BioSciences Raises £10M To Advance Innate Cell Therapy

                            Details : The proceeds will be used to advance the Company’s immunomodulatory alpha neutrophils (IMANs) into clinical trials, a type of super enhanced neutrophil that can kill cancer cells.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : Immunomodulatory Alpha Neutrophils

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Sijbrandij Foundation

                            Deal Size : $13.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neutrophil-based Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Innovate UK

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            LIfT BioSciences Gets UK Grant For IMAN Cell Therapy Development

                            Details : The grant will enable LIfT to show how its immunomodulatory alpha neutrophils recruit immune cells in vivo to attack tumours using a new type of translational humanised mouse model.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Neutrophil-based Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Innovate UK

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha Neutrophil-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LIfT Biosciences Announces Data Demonstrating Potent Killing of Pancreatic Cancer Tumouroids

                            Details : An Immunomodulatory Alpha Neutrophil (IMAN) exhibits a dual mode of action that enables them to be both exceptional cytotoxic directly and immunomodulatory to recruit the rest of the immune system also to destroy solid tumours like pancreatic cancer tumo...

                            Brand Name : Undiclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 04, 2023

                            Lead Product(s) : Alpha Neutrophil-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immunomodulatory Alpha Neutrophil

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LIfT BioSciences Announces Breakthrough Preclinical Data Demonstrating the Dual Mode of Action Commonly Believ...

                            Details : Pre-clinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities, as it stimulated CD4, CD8, NK cells increasing tumour cell death.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : Immunomodulatory Alpha Neutrophil

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neutrophil Progenitor-based Leukocyte Infusion Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Minaris

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership

                            Details : The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid t...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 16, 2023

                            Lead Product(s) : Neutrophil Progenitor-based Leukocyte Infusion Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Minaris

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed

                            LIfT Biosciences

                            United Kingdom arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neutrophil based Leukocyte Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Starbloom Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LIfT BioSciences Investors Increase Investment in LIfT and Johnson and Johnson Welcomes LIfT into JLABS

                            Details : N-LIfT (neutrophil only leukocyte infusion therapy) works by effectively transferring the innate immunity that some exceptional people naturally have in their body from their stem cells to cancer patients.

                            Brand Name : N-LIfT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 19, 2022

                            Lead Product(s) : Neutrophil based Leukocyte Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Starbloom Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth